Program
apixaban
Also written as “Apixaban”, “Apixaban 5 MG” and “Apixaban 5 mg Oral Tablet”.
Its studies are mostly in Venous Thrombosis · Atrial Fibrillation · Thrombosis · Acute Coronary Syndrome · Venous Thromboembolism, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 260 open or running | phase 4since Jun 6, 2013 | Nov 22, 2004 | none ahead |
| Pfizer | 60 open or running | phase 4since Feb 5, 2014 | Nov 5, 2008 | none ahead |
| Artivion | 10 open or running | phase 3since Oct 9, 2019 | Oct 9, 2019 | none ahead |
| Dexa Medica Group | 10 open or running | phase 1since Feb 5, 2025 | Feb 5, 2025 | none ahead |
| Humanis Saglık Anonim Sirketi | 10 open or running | phase 1since Sep 4, 2023 | Sep 4, 2023 | none ahead |
| scotmann-pharmaceuticals | 10 open or running | phase 2since Oct 21, 2021 | Oct 21, 2021 | none ahead |
| TAHO Pharmaceuticals | 10 open or running | early phase 1since Jul 24, 2023 | Jul 24, 2023 | none ahead |
Also a collaborator on its studies: link-medical-research-ab, parexel and pt-equilab-international.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 20 studies since Nov 22, 2004.
- Jan 10, 20143 phase 1 studiesBristol-Myers Squibb · NCT02034591, NCT02034578, NCT02034565
- Feb 5, 2014Phase 4 study in Atrial FibrillationPfizer · NCT02100228 · 1,500 enrolled · United States, Belgium, Canada and more
- Mar 28, 2014Phase 1 study in ThrombosisBristol-Myers Squibb · NCT02101112 · 69 enrolled
- Oct 9, 20142 phase 1 studies in N/A - Healthy SubjectsBristol-Myers Squibb · NCT02262533, NCT02262520
- Jan 21, 2015Phase 3 study in LymphomaBristol-Myers Squibb · NCT02369653 · 512 enrolled · United States, Australia, Belgium and more
- Apr 9, 2015Phase 4 study in Acute Coronary SyndromeBristol-Myers Squibb · NCT02415400 · 4,614 enrolled · United States, Argentina, Australia and more
- May 26, 2015Phase 4 study in Venous ThromboembolismBristol-Myers Squibb · NCT02464969 · 229 enrolled · United States, Australia, Austria and more
- Sep 19, 2016Phase 1 study in Venous ThromboembolismBristol-Myers Squibb · NCT02912234 · 20 enrolled · United States
- Nov 18, 2016Phase 2 study in ThrombosisBristol-Myers Squibb · NCT02981472 · 192 enrolled · United States, Argentina, Australia and more
- Oct 9, 2019Artivion's first study: phase 3 study in Aortic Valve DiseaseNew to ArtivionArtivion · NCT04142658 · 863 enrolled · United States
- Oct 21, 2021scotmann-pharmaceuticals's first study: phase 2 study in COVID-19New to scotmann-pharmaceuticalsscotmann-pharmaceuticals · NCT05088928 · 40 enrolled · Pakistan
- Jul 24, 2023TAHO Pharmaceuticals's first study: early phase 1 study in FastingNew to TAHO PharmaceuticalsTAHO Pharmaceuticals · NCT05995119 · 12 enrolled · United States
- Sep 4, 2023Humanis Saglık Anonim Sirketi's first study: phase 1 study in Antithrombic DrugNew to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT06043297 · 30 enrolled · India
- Feb 5, 2025Dexa Medica Group's first study: phase 1 study in HealthNew to Dexa Medica GroupDexa Medica Group · NCT06817811 · 24 enrolled · Indonesia
TargetBeta
“Coagulation factor X inhibitor”ChEMBL 37, by rule
Other programs on F10
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Rivaroxabanrule | Bayer | phase 4 | 77 |
| emicizumabrule | Hoffmann-La Roche | phase 4 | 13 |
| Factor Xrule | kedrion-s-p-a | phase 3 | 1 |
Studies
All 37 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06817811Health · Indonesia | 1 | Completed | Dexa Medica Group | Apr 24, 2021 | 24 |
| NCT06043297Antithrombic Drug · India | 1 | Completed | Humanis Saglık Anonim Sirketi | Mar 6, 2023 | 30 |
| NCT05995119Fasting · United States | Early 1 | Completed | TAHO Pharmaceuticals | Dec 28, 2022 | 12 |
| NCT05088928COVID-19 · Pakistan | 2 | UNKNOWN | scotmann-pharmaceuticals | May 30, 2022 | 40 |
| NCT04142658Aortic Valve Disease · United States | 3 | Terminated | Artivion | Dec 12, 2022 | 863 |
| NCT02981472Thrombosis · United States, Argentina, Australia and more | 2 | Completed | Bristol-Myers Squibb | Oct 18, 2021 | 192 |
| NCT02912234Venous Thromboembolism · United States | 1 | Completed | Bristol-Myers Squibb | Oct 2016 | 20 |
| NCT02464969Venous Thromboembolism · United States, Australia, Austria and more | 4 | Completed | Bristol-Myers Squibb | Apr 30, 2024 | 229 |
| NCT02415400Acute Coronary Syndrome · United States, Argentina, Australia and more | 4 | Completed | Bristol-Myers Squibb | Nov 10, 2018 | 4,614 |
| NCT02369653Lymphoma · United States, Australia, Belgium and more | 3 | Completed | Bristol-Myers Squibb | Jul 7, 2021 | 512 |
| NCT02262533N/A - Healthy Subjects · United States | 1 | Completed | Bristol-Myers Squibb | Jun 2007 | 15 |
| NCT02262520N/A - Healthy Subjects | 1 | Completed | Bristol-Myers Squibb | Mar 2006 | 24 |
| NCT02101112Thrombosis | 1 | Completed | Bristol-Myers Squibb | May 2014 | 69 |
| NCT02100228Atrial Fibrillation · United States, Belgium, Canada and more | 4 | Completed | Pfizer | Feb 8, 2017 | 1,500 |
| NCT02034591Healthy Subjects · United States | 1 | Completed | Bristol-Myers Squibb | Nov 2011 | 37 |
| NCT02034578Healthy Volunteers · United States | 1 | Completed | Bristol-Myers Squibb | Aug 2011 | 75 |
| NCT02034565Healthy Volunteers · United States | 1 | Completed | Bristol-Myers Squibb | Mar 2010 | 48 |
| NCT01884350Non-valvular Atrial Fibrillation · Belgium, France, Germany and more | 4 | Completed | Bristol-Myers Squibb | Jan 20, 2016 | 1,217 |
| NCT01884337Anticoagulation · India | 4 | Completed | Bristol-Myers Squibb | Jun 4, 2018 | 557 |
| NCT01780987Venous Thrombosis · Japan | 3 | Completed | Pfizer | Sep 2014 | 80 |
| NCT01707394Thromboembolism · United States, Australia, Canada and more | 1 | Completed | Bristol-Myers Squibb | Jun 30, 2020 | 49 |
| NCT01437839Healthy · Singapore | 1 | Completed | Pfizer | Oct 2011 | 22 |
| NCT01340586Kidney Failure, Chronic · United States | 1 | Completed | Bristol-Myers Squibb | Sep 2011 | 18 |
| NCT01195727Venous Thromboembolism · United States, Belgium, Canada and more | 1 | Terminated | Bristol-Myers Squibb | Jun 14, 2012 | 13 |
| NCT00914641Thrombosis · United States | 1 | Completed | Pfizer | Aug 2009 | 16 |
| NCT00852397Acute Coronary Syndrome · Japan | 2 | Terminated | Pfizer | Dec 2010 | 151 |
| NCT00831441Acute Coronary Syndrome · United States, Argentina, Australia and more | 3 | Terminated | Bristol-Myers Squibb | Mar 2011 | 7,484 |
| NCT00787150Atrial Fibrillation · Japan | 2 | Completed | Pfizer | Sep 2009 | 222 |
| NCT00643201Venous Thrombosis · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Mar 2013 | 5,614 |
| NCT00633893Venous Thrombosis · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Aug 2012 | 2,711 |
| NCT00496769Atrial Fibrillation · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Nov 30, 2010 | 6,421 |
| NCT00457002Venous Thrombosis · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | May 2011 | 6,758 |
| NCT00452530Venous Thrombosis · Austria, Belgium, Brazil and more | 3 | Completed | Bristol-Myers Squibb | Jan 2009 | 3,221 |
| NCT00412984Atrial Fibrillation · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | May 25, 2011 | 20,976 |
| NCT00313300Acute Coronary Syndrome · United States, Austria, Belgium and more | 2 | Completed | Bristol-Myers Squibb | May 2008 | 1,741 |
| NCT00252005Venous Thrombosis · United States, Australia, Austria and more | 2 | Completed | Bristol-Myers Squibb | Feb 2007 | 520 |
| NCT00097357Venous Thrombosis · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Dec 2005 | 1,238 |
How it is read
Names in the registry
- “Apixaban”, 38 entries
- “Apixaban 5 MG”, 2 entries
- “apixaban”, 2 entries
- “Apixaban 5 mg Oral Tablet”, 1 entry
- “Apixaban 5MG”, 1 entry
Conditions, from the studies’ own filings
- Venous Thrombosis, 7 studies
- Atrial Fibrillation, 6 studies
- Thrombosis, 4 studies
- Acute Coronary Syndrome, 4 studies
- Venous Thromboembolism, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.